2-oxa-5-azabicyclo[2.2.2]octane hydrochloride | 1408075-32-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-oxa-5-azabicyclo[2.2.2]octane hydrochloride
• 英文别名: 2-oxa-5-azabicyclo[2.2.2]octane;hydrochloride
• CAS: 1408075-32-0
• 化学式: C₆H₁₁NO*(x)ClH
• 分子量: 149.62
• InChiKey: HIDMFWUHQBIUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.56
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(6-chloro-2-methoxypyrimidin-4-yl)-5-methyl-6-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazole 、 2-oxa-5-azabicyclo[2.2.2]octane hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-(2-methoxy-6-(5-methyl-6-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-1-yl)pyrimidin-4-yl)-2-oxa-5-azabicyclo[2.2.2]octane
  参考文献：
  名称：

  [EN] COMPOUNDS
  [FR] COMPOSÉS

  摘要：

  提供了抑制LRRK2激酶活性的新化合物，以及它们的制备方法、含有它们的组合物以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的用途，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。

  公开号：

  WO2018137593A1

文献信息

• Compounds
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US10858367B2

  公开（公告）日：2020-12-08

  Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本文提供了抑制 LRRK2 激酶活性的新型化合物、其制备工艺、含有这些化合物的组合物以及它们在治疗或预防与 LRRK2 激酶活性相关或以 LRRK2 激酶活性为特征的疾病（例如帕金森病、阿尔茨海默病和肌萎缩性脊髓侧索硬化症 (ALS)）中的用途。
• Substituted 6-azabenzimidazole compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11203591B2

  公开（公告）日：2021-12-21

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

  本公开一般涉及某些 6-氮杂苯并咪唑化合物、包含所述化合物的药物组合物以及制造和使用所述化合物和药物组合物的方法。本文公开的化合物和组合物可用于治疗或预防可被造血祖细胞激酶 1（HPK1）抑制剂改变的疾病、失调或感染，如 HBV、HIV、癌症和/或过度增殖性疾病。
• SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS
  申请人：GILEAD SCIENCES, INC.

  公开号：EP3873903A1

  公开（公告）日：2021-09-08
• SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20210115037A1

  公开（公告）日：2021-04-22

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.